Global Influenza Vaccine Market Booming Worldwide with Latest Trend and Future Scope by 2028

The global influenza vaccine market is expected to grow at a CAGR of 7.0% during the forecast period (2022-2028). Influenza is a viral infection that affects the respiratory system and is caused by the flu virus. The influenza virus is contagious and spreads through respiratory droplets. It can also be passed from one person to another through conversation or physical contact. The influenza virus is constantly spreading, resulting in regional epidemics and outbreaks that kill thousands of people. The changing nature of the virus necessitates an annual vaccine strain change to match the influenza virus strain.

Healthcare organizations around the world, such as the Centers for Disease Control and Prevention (CDC), have suggested vaccines such as baloxavir marboxil (Xofluza) for the treatment of influenza symptoms in patients. Influenza vaccines contain three types of influenza viruses, such as influenza type A with H3N2 virus strain, influenza type A with H1N1 virus strain, and influenza type B virus strain. During the forecasted period, an increase in the prevalence of influenza epidemics and seasonal outbreaks is likely to boost the market growth. Other key factors driving the market growth include an increase in government support and surveillance regarding influenza vaccination on a national and global level to monitor the supply, distribution, and administration of flu vaccines. Furthermore, the rising government funding and increased investment by leading market players have facilitated the launch of therapeutically effective vaccines, propelling the global influenza vaccine market.

Owing to the coronavirus pandemic, several healthcare organizations’ immunization camps and programs was impacted. Vaccination rates for the flu have reached an all-time high during the pandemic, owing to a push by various healthcare providers and the government, which is providing free vaccination to citizens. The development of a novel vaccine is a lengthy process that takes about 10-15 years to complete and test for safety and efficacy. Regulatory requirements for clinical trials differ by country, potentially delaying the development of vaccines and limiting the market growth. Many companies are assisting with the distribution, including Sanofi SA, Emergent BioSolutions Inc., and F. Hoffmann-La Roche Ltd. On the other hand, owing to the strict regulations during clinical trials that extend vaccine delivery timelines, many countries had experienced shortages and delays in vaccine approvals and availability.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Vaccine Type
  • By Technology
  • By Age Group
  • By Route of Administration
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- AstraZeneca plc, GlaxoSmithKline plc, and Merck & Co., Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impact the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Influenza Vaccine Market Report by Segment

By Vaccine Type

• Quadrivalent
• Trivalent

By Technology

• Egg-Based
• Cell Culture

By Age Group

• Pediatric
• Adult

By Route of Administration

• Injection
• Nasal Spray